Last reviewed · How we verify
NCT05639803
A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults
Phase 1 trial testing PEGIFNα1b in Herpes Zoster in 50 participants. Completed in 22 October 2020.
22 October 2020
Quick facts
| Lead sponsor | Shanghai Institute Of Biological Products |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 7 July 2020 |
| Primary completion | 22 October 2020 |
| Estimated completion | 22 October 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- PEGIFNα1b — full drug profile →
- Placebo
Conditions studied
- Herpes Zoster — all drugs for Herpes Zoster →
Sponsor
Shanghai Institute Of Biological Products
Who can join
Adults 18 to 70, any sex, with Herpes Zoster. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase I，randomized, double-blind, placebo controlled,dose escalated,single administrated clinical trial in Chinese healthy adult's volunteers. In the trial, it is planned to enroll 50 subjects, randomized to 5 dosage groups to receive the test drug and the placebo control.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05639803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Herpes Zoster
Currently open trials in the same condition.
- NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting
- NCT07307170 — The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster · NA · recruiting
- NCT07293065 — A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) · Phase 3 · active not recruiting
- NCT07361796 — The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes · NA · recruiting
- NCT07378046 — The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster · NA · recruiting
Other Shanghai Institute Of Biological Products trials
Trials by the same sponsor.
- NCT07363837 — Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants · Phase 1, PHASE2 · not yet recruiting
- NCT07327398 — Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 2 · not yet recruiting
- NCT07253675 — Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo · Phase 2 · not yet recruiting
- NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
- NCT07205198 — A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects. · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05639803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Institute Of Biological Products
- Last refreshed: 6 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05639803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing